A Comprehensive Immunological Analysis in Chronic Fatigue Syndrome

A detailed analysis of cell‐mediated and antibody‐mediated immunity was performed in 20 CDC‐defined patients with chronic fatigue syndrome (CFS) and 20 age‐ and sex‐matched healthy controls. CD3 +, CD4 +, CD8 +, and CD20+ lymphocytes were comparable in two groups. Natural killer cells as defined by CD16, CD56 and CD57 antigens were significantly reduced in CFS. A significant increase in the proportions orCD4+ICAM 1+ T cells was observed in CFS. Monocytes from CFS displayed increased density (as determined by mean fluorescence channel numbers) of intercellular adhesion molecule 1 (ICAM‐1) and lymphocyte function associated antigen 1 (LFA‐1). but showed decreased enhancing response to recombinant interferon‐γ in vitro. The lymphocyte DNA synthesis in response lo phytohaemoglobulin (PHA). Concanavalin A (Con A) and pokeweed mitogen (PWM) was normal but the response to soluble antigens was significantly reduced. Serum IgM. IgG, IgA, and IgG sublclasses were normal. In vivo specific antibody response to pneumococcus vaccine was depressed in CFS. Forty percent of patients showed titres of anti‐human herpes virus 6 (anli‐HHV‐6) antibody higher than that in the controls (≤ 1/80). These data suggest immunological dysfunction in patients with chronic fatigue syndrome. The significance of these observations is discussed.

[1]  I. Hickie,et al.  Immunological abnormalities in the chronic fatigue syndrome , 1990, The Medical journal of Australia.

[2]  D. Wakefield,et al.  Immunological abnormalities in the chronic fatigue syndrome (for editorial comment, see page 117) , 1989 .

[3]  Michael Loran Dustin,et al.  The induction of intercellular adhesion molecule 1 (ICAM-1) expression on human fetal astrocytes by interferon-λ, tumor necrosis factor α, lymphotoxin, and interleukin-1: relevance to intracerebral antigen presentation , 1989, Journal of Neuroimmunology.

[4]  J. Prieto,et al.  Naloxone‐Reversible Monocyte Dysfunction in Patients with Chronic Fatigue Syndrome , 1989, Scandinavian journal of immunology.

[5]  J. Prieto,et al.  Deficient display of CD3 on lymphocytes of patients with chronic fatigue syndrome. , 1989, The Journal of infectious diseases.

[6]  D. Bell,et al.  Interleukin-2 and the chronic fatigue syndrome. , 1989, Annals of Internal Medicine.

[7]  J. Prieto,et al.  GAMMA-INTERFERON AND CHRONIC FATIGUE SYNDROME , 1988, The Lancet.

[8]  S. Nakamura,et al.  Human B-lymphotropic virus (human herpesvirus-6). , 1988, Journal of virological methods.

[9]  B. Bannister,et al.  INTERFERON PRODUCTION IN POSTVIRAL FATIGUE SYNDROME , 1988, The Lancet.

[10]  A. Komaroff,et al.  IgG SUBCLASS DEFICIENCIES IN CHRONIC FATIGUE SYNDROME , 1988, The Lancet.

[11]  C. I. Smith,et al.  IgG SUBCLASS DEFICIENCY AND CHRONIC FATIGUE SYNDROME , 1988, The Lancet.

[12]  Michael Loran Dustin,et al.  Adhesion of T lymphoblasts to epidermal keratinocytes is regulated by interferon gamma and is mediated by intercellular adhesion molecule 1 (ICAM-1) , 1988, The Journal of experimental medicine.

[13]  James F. Jones,et al.  Chronic fatigue syndrome: a working case definition. , 1988, Annals of internal medicine.

[14]  R. Read,et al.  IgG1 SUBCLASS DEFICIENCY IN PATIENTS WITH CHRONIC FATIGUE SYNDROME , 1988, The Lancet.

[15]  G. Yousef,et al.  CHRONIC ENTEROVIRUS INFECTION IN PATIENTS WITH POSTVIRAL FATIGUE SYNDROME , 1988, The Lancet.

[16]  Timothy A. Springer,et al.  Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1) , 1987, Cell.

[17]  M. Caligiuri,et al.  Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. , 1987, Journal of immunology.

[18]  D. Wakefield,et al.  PATHOPHYSIOLOGY OF MYALGIC ENCEPHALITIS , 1987, The Lancet.

[19]  G. Krueger,et al.  PERSISTENT FATIGUE AND DEPRESSION IN PATIENT WITH ANTIBODY TO HUMAN B-LYMPHOTROPIC VIRUS , 1987, The Lancet.

[20]  P. Pinsky,et al.  A cluster of patients with a chronic mononucleosis-like syndrome. Is Epstein-Barr virus the cause? , 1987, JAMA.

[21]  M. Kaplan,et al.  Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. , 1986, Science.

[22]  T. Waldmann,et al.  Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. , 1985, The New England journal of medicine.

[23]  W. Henle,et al.  Characteristic T cell dysfunction in patients with chronic active Epstein-Barr virus infection (chronic infectious mononucleosis). , 1985, Journal of immunology.

[24]  B. Safai,et al.  Deficient autologous mixed lymphocyte reaction in Kaposi's sarcoma associated with deficiency of Leu-3+ responder T cells. , 1983, The Journal of clinical investigation.

[25]  Michael Loran Dustin,et al.  The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system. , 1987, Annual review of immunology.

[26]  E. Tournier-Lasserve,et al.  T-cell Subsets in Multiple Sclerosis , 1986 .

[27]  R. Davey,et al.  Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. , 1985, Annals of internal medicine.

[28]  James F. Jones,et al.  Evidence for Active Epstein-Barr Virus Infection in Patients with Persistent, Unexplained Illnesses: Elevated Anti-Early Antigen Antibodies , 1985 .